Marianna Paulis

Dr. Marianna Paulis

CNR -IRGB, UOS of Milan, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2008 in Human Molecular Genetics
Verified
Journal Article
Closed access
EREkaterina Revenkova
Ekaterina Revenkova
MFMaria Luisa Focarelli
Maria Luisa Focarelli
LSLucia Susani
Lucia Susani
MPMarianna Paulis
Marianna Paulis
MBMaria Teresa Bassi
Maria Teresa Bassi
Antonio MusioAntonio Musio
Antonio Musio
Cornelia de Lange syndrome (CdLS) is a clinically heterogeneous developmental disorder characterized by facial dysmorphia, upper limb malformations, growth and cognitive retardation. Mutations in the sister chromatid cohesion factor genes NIPBL, SMC1A and SMC3 are present in approximately 65% of CdLS patients. In addition to their canonical roles in chromosome segregation, the cohesin proteins are involved in other biological processes such as regulation of gene expression, DNA repair and maintenance of genome stability. To gain insights into the molecular basis of CdLS, we analyzed the affinity of mutated SMC1A and SMC3 hinge domains for DNA. Mutated hinge dimers bind DNA with higher affinity than wild-type proteins. SMC1A- and SMC3-mutated CdLS cell lines display genomic instability and sensitivity to ionizing radiation and interstrand crosslinking agents. We propose that SMC1A and SMC3 CdLS mutations affect the dynamic association between SMC proteins and DNA, providing new clues to the underlying molecular cause of CdLS.

22 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNicolò Salvarani
Nicolò Salvarani
SCSilvia Crasto
Silvia Crasto
MMMichele Miragoli
Michele Miragoli
ABAlessandro Bertero
Alessandro Bertero
MPMarianna Paulis
Marianna Paulis
Elisa Di PasqualeElisa Di Pasquale
Elisa Di Pasquale
Mutations in LMNA, which encodes the nuclear proteins Lamin A/C, can cause cardiomyopathy and conduction disorders. Here, we employ induced pluripotent stem cells (iPSCs) generated from human cells carrying heterozygous K219T mutation on LMNA to develop a disease model. Cardiomyocytes differentiated from these iPSCs, and which thus carry K219T-LMNA, have altered action potential, reduced peak sodium current and diminished conduction velocity. Moreover, they have significantly downregulated Nav1.5 channel expression and increased binding of Lamin A/C to the promoter of SCN5A, the channel’s gene. Coherently, binding of the Polycomb Repressive Complex 2 (PRC2) protein SUZ12 and deposition of the repressive histone mark H3K27me3 are increased at SCN5A. CRISPR/Cas9-mediated correction of the mutation re-establishes sodium current density and SCN5A expression. Thus, K219T-LMNA cooperates with PRC2 in downregulating SCN5A, leading to decreased sodium current density and slower conduction velocity. This mechanism may underlie the conduction abnormalities associated with LMNA-cardiomyopathy.

21 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PMPietro Giuseppe MAZZARA
Pietro Giuseppe MAZZARA
SMSharon Muggeo
Sharon Muggeo
MLMirko Luoni
Mirko Luoni
LMLuca Massimino
Luca Massimino
MZMattia Zaghi
Mattia Zaghi
VBVania Broccoli
Vania Broccoli
Friedreich’s ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron. Herein, we generate dorsal root ganglia organoids (DRG organoids) by in vitro differentiation of human iPSCs. Bulk and single-cell RNA sequencing show that DRG organoids present a transcriptional signature similar to native DRGs and display the main peripheral sensory neuronal and glial cell subtypes. Furthermore, when co-cultured with human intrafusal muscle fibers, DRG organoid sensory neurons contact their peripheral targets and reconstitute the muscle spindle proprioceptive receptors. FRDA DRG organoids model some molecular and cellular deficits of the disease that are rescued when the entire FXN intron 1 is removed, and not with the excision of the expanded GAA tract. These results strongly suggest that removal of the repressed chromatin flanking the GAA tract might contribute to rescue FXN total expression and fully revert the pathological hallmarks of FRDA DRG neurons.

16 September 2016 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
VMVasco Meneghini
Vasco Meneghini
Giacomo FratiGiacomo Frati
Giacomo Frati
DSDavide Sala
Davide Sala
SCSilvia De Cicco
Silvia De Cicco
MLMarco Luciani
Marco Luciani
AGAngela Gritti
Angela Gritti
Allogeneic fetal-derived human neural stem cells (hfNSCs) that are under clinical evaluation for several neurodegenerative diseases display a favorable safety profile, but require immunosuppression upon transplantation in patients. Neural progenitors derived from patient-specific induced pluripotent stem cells (iPSCs) may be relevant for autologous ex vivo gene-therapy applications to treat genetic diseases with unmet medical need. In this scenario, obtaining iPSC-derived neural stem cells (NSCs) showing a reliable “NSC signature” is mandatory. Here, we generated human iPSC (hiPSC) clones via reprogramming of skin fibroblasts derived from normal donors and patients affected by metachromatic leukodystrophy (MLD), a fatal neurodegenerative lysosomal storage disease caused by genetic defects of the arylsulfatase A (ARSA) enzyme. We differentiated hiPSCs into NSCs (hiPS-NSCs) sharing molecular, phenotypic, and functional identity with hfNSCs, which we used as a “gold standard” in a side-by-side comparison when validating the phenotype of hiPS-NSCs and predicting their performance after intracerebral transplantation. Using lentiviral vectors, we efficiently transduced MLD hiPSCs, achieving supraphysiological ARSA activity that further increased upon neural differentiation. Intracerebral transplantation of hiPS-NSCs into neonatal and adult immunodeficient MLD mice stably restored ARSA activity in the whole central nervous system. Importantly, we observed a significant decrease of sulfatide storage when ARSA-overexpressing cells were used, with a clear advantage in those mice receiving neonatal as compared with adult intervention. Thus, we generated a renewable source of ARSA-overexpressing iPSC-derived bona fide hNSCs with improved features compared with clinically approved hfNSCs. Patient-specific ARSA-overexpressing hiPS-NSCs may be used in autologous ex vivo gene therapy protocols to provide long-lasting enzymatic supply in MLD-affected brains.

26 July 2012 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
NINadia Lo Iacono
Nadia Lo Iacono
HBHarry C Blair
Harry C Blair
Pietro Luigi PolianiPietro Luigi Poliani
Pietro Luigi Poliani
VMVeronica Agata Marrella
Veronica Agata Marrella
FFFrancesca Ficara
Francesca Ficara
CSCristina Sobacchi
Cristina Sobacchi
In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT). However, this approach is not effective in the recently identified form carrying mutations in the receptor activator of NF-κB ligand (RANKL) gene. In this subset, therapy replacement approach based on RANKL delivery has a strong rationale. Here we demonstrate that the systematic administration of RANKL for 1 month to Rankl−/− mice, which closely resemble the human disease, significantly improves the bone phenotype and has beneficial effects on bone marrow, spleen and thymus; major adverse effects arise only when mice are clearly overtreated. Overall, we provide evidence that the pharmacological administration of RANKL represents the appropriate treatment option for RANKL-deficient ARO patients, to be validated in a pilot clinical trial. © 2012 American Society for Bone and Mineral Research.

16 September 2009 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
MFMaria Luisa Focarelli
Maria Luisa Focarelli
SSSamuela Soza
Samuela Soza
LMLinda Mannini
Linda Mannini
MPMarianna Paulis
Marianna Paulis
AMAlessandra Montecucco
Alessandra Montecucco
Antonio MusioAntonio Musio
Antonio Musio